Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
ANVIMO will be available in dosages of 240 mg and 480 mg
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
Subscribe To Our Newsletter & Stay Updated
